Recalls and manufacturing woes hit J&J sales in Q4
This article was originally published in Scrip
The severe impact of recalls of certain OTC medicines and the suspension of manufacturing at one of its facilities has resulted in J&J reporting a significant drop in sales by 5.5% to $15.6 billion for the fourth quarter of 2010, "a lower level of sales than expected", the company conceded in a conference call.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.